You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The firms aim to combine PerkinElmer 's Ordered Data Interpretation Network and FDNA's Face2Gene facial analysis software to target emerging markets.
Regulators in the country granted additional approval of the test as a companion diagnostic for Rozlytrek, marketed in Japan by Roche's Chugai Pharmaceutical.
Under the partnership, Heidelberg-based Eluthia will become the primary distributor of BGI's NIFTY noninvasive prenatal test in Germany.
IDT and Beijing-based ChosenMed plan to develop large pan-cancer panels as part of the Cancer Genome Atlas of China.
Researchers at Harvard, Peking University, and Yikon Genomics suggested that their noninvasive test is more specific than the prevailing biopsy-based method.
The Japan News writes that Japan needs to seize the opportunity to ensure that a wide number of people benefit from personalized cancer treatments.
AnchorDx, based in Guangzhou in southern China, will use Illumina's MiSeqDx sequencer to develop IVD cancer test kits and data analysis software.
In PNAS this week: links between lung adenocarcinoma and lncRNA, algorithm to impute and cluster Hi-C interaction profiles from single cells, and more.
With funding from the Bill and Melinda Gates Foundation, the Biohub will help implement metagenomic sequencing for infectious disease projects in 10 countries.
New US Department of Commerce rules will affect supercomputing in China, according to the Wall Street Journal.
The Washington Post reports on researchers' efforts to determine the effect of an increasingly common SARS-CoV-2 mutation.
Florida Politics reports Florida's law barring life, long-term care, and disability insurers from using genetic information in coverage decisions went into effect at the beginning of July.
A new analysis finds a link between popular media coverage of a scientific study and how often that paper is cited.
In Nature this week: CRISPR approaches to editing plant genomes, way to speed up DNA-PAINT, and more.